VMware Engine is a fully managed offering that lets enterprises run existing virtual machines on Google Cloud infrastructure.

Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it has filed with the Swedish Medical Product Agency and the Institutional Review Board to initiate a Phase 2 study of its oral Endoxifen for the reduction of mammographic breast density (MBD). MBD is an emerging public health issue affecting more than 10 million women in the United States. Studies conducted by others have shown that MBD increases the risk of developing breast cancer, and reducing MBD can reduce the incidence of breast cancer.

Atos, a global leader in digital transformation, today announced the company has appointed Bryan Ireton as CEO, North America, effective June 1st.

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced positive interim results from its Phase 2 study of oral Endoxifen to treat breast cancer in the window of opportunity between diagnosis of breast cancer and surgery. A statistically significant (p = 0.031) reduction of about 74% in tumor cell proliferation was achieved over the 22 days of dosing. Proliferation was measured by Ki-67, a recognized standard measurement of breast cancer cell proliferation.

Atossa Therapeutics, Inc. (ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced the successful results from in vitro testing of AT-H201, Atossa’s proprietary COVID-19 drug candidate. The preliminary study results show that AT-H201 inhibits SARS-CoV-2 infectivity of VERO cells in a laboratory culture, which are the standard cell types being used to study infectivity of the coronavirus. AT-H201 components inhibited SARS-CoV-2 from infecting VERO cells in a laboratory culture.

Atossa Therapeutics, Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced recent progress with its Phase 2 study administering oral Endoxifen in the “window of opportunity” between diagnosis of breast cancer and surgery, as well as the company’s proposed Phase 2 clinical trial to reduce mammographic breast density (MBD). Completed treating a sufficient number of patients to permit an initial report of study results from the pilot portion of the study.

Every February 4th is World Cancer Day , the global uniting initiative led by the Union for International Cancer Control (UICC). By raising worldwide awareness, improving education and catalyzing personal, ...

Inside The Chart: Game Changer – Men's Basketball — Georgia Tech Yellow Jackets  Georgia Tech Official Athletic Site

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it has contracted with Stockholm South General Hospital in Sweden to conduct a Phase 2 study of Atossa’s proprietary oral Endoxifen to reduce mammographic breast density (MBD) in women. MBD is an emerging public health issue, as studies conducted by others have shown that MBD increases the risk of developing breast cancer and that reducing MBD can reduce the incidence of breast cancer.

Atossa Therapeutics, Inc. (ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need, today announced that it has contracted with NYC Health + Hospitals/Metropolitan in New York City to conduct the NY HOPE Study of Atossa’s proprietary combination drug therapy called AT-H201. The NY HOPE Study will evaluate AT-H201 in COVID-19 patients on ventilators with the goal of reducing the amount of time on ventilators. “We are honored to be working with NYC Health + Hospitals/Metropolitan and Dr. Getaw Hassen, who are on the front lines of this unprecedented health crisis,” stated Dr. Steven Quay, President and CEO of Atossa Therapeutics.

The global digital workplace market size is expected to reach USD 54.2 billion by 2027, expanding at a CAGR of 11.3% from 2020 to 2027, according to a new report by Grand View Research, Inc. The availability of new software and tools, demand for remote workin…

France data center market size is expected to grow at a CAGR of around 5% during the period 2019−2025. This market research report includes data-driven and deep market insights on the impact of COVID-19 across geographies, segments, and vendor landscape. Leve…

SEATTLE, Feb. 05, 2020 -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast.

Role models at BAE Systems, Accenture, Atos, IBM and Tech Manchester highlighted as WeAreTheCity unveils pipeline of female talent

Atossa Therapeutics, Inc. (ATOS), has applied to the FDA for approval to commence a clinical study of its proprietary drug, AT-H201, in COVID-19 patients on mechanical ventilation. AT-H201 is a novel formulation of two pharmaceuticals previously approved by the FDA for other diseases. The goal of the clinical trial, called the HOPE Study, is to demonstrate improved lung function and reduce the amount of time that COVID-19 patients are on ventilators.

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that its corporate name change from "Atossa Genetics Inc." to "Atossa Therapeutics, Inc." became effective at 12:01 a.m. ET today, January 6, 2020. "Over the last several years, we have transitioned the Company’s focus on developing therapies to treat breast cancer, breast density and other breast conditions," said Steve Quay, Ph.D., M.D., president and CEO of Atossa.

The world’s focus has zeroed in on healthcare companies. Hardly a surprising turn of events in these pandemic driven times. The search for a treatment or vaccine for COVID-19 has thrust into the limelight a host of smaller operators, who otherwise would have most likely remained under the wider public’s radar. The latest to join the race for a viable treatment is nano-cap Atossa Genetics (ATOS).Last week, shares of Atossa shot up by 35% following a launch announcement of a drug development program for COVID-19, called COVID-19 HOPE (AT-H201).The program consists of a combination of two undisclosed drugs already approved by the FDA for other diseases. The goal is to develop a therapy which will reduce the amount of time COVID-19 patients are on ventilators by improving lung function. Due to the large number of COVID-19 patients needing mechanical ventilation, hospitals are facing ventilator shortages, an issue Atossa hopes to solve with its novel offering.The company has filed provisional patent applications for the treatment and plans to apply to the FDA for approval to begin a clinical study under the Coronavirus Treatment Acceleration Program.Performing similarly to how antibodies against the virus would after a patient is vaccinated or immune, the purpose of AT-H201 is to block the ability of the virus to enter the target cells by mimicking the function of the antibodies formed from a vaccine.Maxim’s Jason McCarthy applauds Atossa’s “differentiated approach.” The analyst reiterated a Buy on ATOS along with a $4 price target, which implies an impressive 90% should the analyst’s target be met over the next 12 months. (To watch McCarthy’s track record, click here)McCarthy said, “The COVID pandemic needs testing, therapeutics and a vaccine. In reality, an effective vaccine is likely 12-18+ months away, and that would still be incredibly fast, in our view… As such having adequate testing and therapeutics which can 'blunt' the pandemic is critical, and all options are on the table.” (See Atossa stock analysis on TipRanks) More recent articles from Smarter Analyst: * Microsoft Reveals 4 New Surface Products Including Release Date For $199 Earbuds * All Eyes on Uber, Lyft Ahead of Earnings; Top Analyst Says 'Buy' * U.S. Air Carriers Lose More Than $10 Billion a Month - Report * 2 "Strong Buy" Dividend Stocks Yielding at Least 10%

Atossa Therapeutics, Inc. (ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need, today announced a new drug development program called COVID-19 HOPE. The program uses a novel combination of two drugs that have been previously approved by the FDA for other diseases. The goal of the COVID-19 HOPE program is to develop a therapy to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators.

During 2019, we focused on developing our proprietary drug Endoxifen to reduce mammographic breast density (MBD) and to treat breast cancer after a woman is diagnosed but before her surgery. MBD is an emerging public health issue affecting over 10 million women in the United States.

Physician-scientist and inventor Dr. Steven Quay, MD, PhD, is announcing a new combination treatment with the potential to improve pulmonary function and reduce or eliminate mechanical ventilation in patients with the coronavirus infection. The treatment uses two drugs previously approved by the FDA for other conditions: nebulized (inhaled as a fine mist) heparin combined with N-acetylcysteine (NAC), termed “H-NAC."

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced it has received feedback from the U.S. Food and Drug Administration (FDA) regarding two ongoing programs. The FDA recently provided written input on Atossa’s clinical path for oral Endoxifen to reduce mammographic breast density, or MBD. The input received from the FDA was very useful and will inform Atossa’s clinical trial strategy and study design both in the U.S. and in Stockholm, Sweden where Atossa is planning a Phase 2 study to reduce MBD.

Paris, May 14, 2020 - Atos, a global leader in digital transformation, anticipates what the world will look like after the Covid-19 crisis in a report...

Toyota has celebrated frontline workers, while sponsors like Visa and Bridgestone are honing in on how athletes are adapting to the crisis at home. The post Pivot or pause? With the 2020 Games postponed, Olympics sponsors are adapting their ads appeared first…

MPW earnings call for the period ending March 31, 2020.

Physician-scientist and inventor Dr. Steven Quay, MD, PhD announced today that his proprietary model of COVID-19 case growth predicts that the United States as a whole will be able to declare a SARS-CoV-2 “cease fire” on April 23, 2020, although individual states will continue to battle the pandemic. Many of the Administration’s initiatives have been successfully used by Taiwan to contain the virus and then permit the country to return to near normal.

(Bloomberg) -- The European Union’s tech chief Thierry Breton said Facebook Inc. will face more regulation if Mark Zuckerberg fails to assuage concerns about business practices, including around market power, as the two men went toe-to-toe in a live-streamed …

BlackBerry today announced, after passing the stringent requirements, its Government Mobility Suite has achieved FedRAMP authorization. Back in June of last year, BlackBerry announced its Government Mobility Suite had reached FedRAMP ready status and today, …

What lots are in the public sector pork barrel? Hardware, software, cloud services, security... plus chatbots and blockchain A group of London NHS trusts has awarded a gaggle of IT resellers, integrators, and service companies a place on a framework contract …

The "Next-Generation 911 - The Future of Public Safety, Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today that it will meet with the U.S. FDA on April 30, 2020. The objective of this meeting is to discuss the clinical development of oral Endoxifen to reduce mammographic breast density (MBD). "This important meeting with the FDA is a critical step in developing our oral Endoxifen for the U.S. market,” commented Janet R. Rea, SVP Regulatory, Quality and Clinical Affairs.

Account Takeover (ATO) attacks happen when a bad actor gains access to a legitimate customer’s eCommerce store account and uses that account for fraud. The impact of ATO attacks A new Riskified survey shows that ATO attacks have a huge negative impact on cust…

SEATTLE, May 13, 2020 -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of.

KEY FINDINGSThe global automated fare collection system market is estimated to grow at a CAGR of 11.51% during the projected period of 2020-2028. The factors influencing the market growth are the increasing use of smartphones, less probability of fraud and co…

RNG earnings call for the period ending March 31, 2020.

Atos North America was recently awarded a multi-year contract with the State of Texas' Department of Information Resources (DIR) to deliver next generation private cloud transformation and artificial intelligence and machine learning capabilities. This modern…

Business Process Outsourcing (BPO) market worldwide is projected to grow by US$108.3 Billion  GlobeNewswire

SEATTLE, March 26, 2020 -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat.

Analyst Anshel Sag takes an in-depth look at NVIDIA's new A100 GPU, featuring the company's new Ampere GPU architecture.